Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 7/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.33 |
| ▸ | PER2 | O15055 | 2/20 | 0.33 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6330806 | 0.90 | P2RX7 (0.36) | P2RX7ALDH1A1TDP1HTR2AHTR2C | |
| SCHEMBL6330114 | 0.89 | P2RX7 (0.43) | P2RX7MAPK14ALDH1A1TDP1HTR2A | |
| SCHEMBL6330148 | 0.87 | MAPK14 (0.35) | P2RX7MAPK14ALDH1A1TDP1HTR2A | |
| SCHEMBL6328298 | 0.87 | HTR2A (0.39) | P2RX7MAPK14HTR2AHTR2C | |
| SCHEMBL6403964 | 0.86 | PTGER1 (0.39) | P2RX7ALDH1A1TDP1PTGER1 | |
| SCHEMBL6329553 | 0.85 | MAPK14 (0.39) | P2RX7MAPK14ALDH1A1TDP1HTR2A | |
| SCHEMBL6327880 | 0.84 | MAPK14 (0.39) | P2RX7MAPK14ALDH1A1TDP1PTGER1 | |
| SCHEMBL6328913 | 0.84 | MAPK14 (0.40) | P2RX7MAPK14ALDH1A1TDP1PTGER1 | |
| SCHEMBL6402503 | 0.82 | SLC6A2 (0.38) | ALDH1A1TDP1HTR2A | |
| SCHEMBL6337834 | 0.82 | HTR6 (0.34) | P2RX7ALDH1A1TDP1HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050085509-A1 | Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO. LTD. (JP) | 2005-04-21 | — | — | US | claimed |
| EP-1447401-A1 | PIPERIDIN-2-ONE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-08-18 | — | — | EP | claimed |
| US-20050085509-A1 | Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO. LTD. (JP) | 2005-04-21 | — | — | US | disclosed |
| EP-1447401-A1 | PIPERIDIN-2-ONE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085509-A1 | Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient | MAPKAP1, MAPK1, MAPK8 | P2RX7 2638/4885MAPK14 64/4885ALDH1A1 2969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.